TRT Blood Test Timing: Exact Draw Windows by Ester (2026)

You get your bloodwork done on TRT. Testosterone comes back at 1,200 ng/dL. You panic, thinking your dose is too high. Your doctor suggests cutting it. But here is the problem: you drew blood 36 hours after your injection, right at peak levels. Had you tested the morning before your next shot, the same protocol would have read 550 ng/dL. Same dose, same week, completely different result.

This is the most common mistake in TRT monitoring, and it happens constantly. The timing of your blood draw relative to your injection determines your result more than almost any other variable. A poorly timed test can lead to unnecessary dose changes, panic over "high" estradiol, or a false sense of security from a "normal" reading that actually reflects a peak, not your baseline exposure.

This guide covers exactly when to draw blood for every testosterone ester, why trough testing is the standard, how often you should be testing, and how the rules change when you move from TRT to a blast.

Why timing your blood draw matters

On injectable testosterone, your levels are not constant. After each injection, testosterone rises to a peak over the first one to five days (depending on the ester), then gradually declines until your next dose. This creates a wave pattern, and where you sample on that wave completely changes the number on your lab report.

How large is the difference? In a pharmacokinetic study of 200 mg intramuscular testosterone cypionate, peak levels averaged 1,112 ng/dL at days four to five, while trough levels at day fourteen dropped to approximately 400 ng/dL (Shoskes et al., 2016). That is a swing of over 700 ng/dL on the same dose, in the same patient, in the same injection cycle.

This matters for every downstream marker too. Estradiol aromatises proportionally to testosterone, so peak E2 tracks peak testosterone. A man who tests at day two post-injection will see estradiol that looks three times higher than at trough (Nankin, 1987). That inflated number is often the trigger for unnecessary aromatase inhibitor use, which creates its own problems (see our estradiol on TRT guide for why crashing E2 is worse than running it slightly high).

Haematocrit is another marker affected by exposure levels. Erythrocytosis risk on injectable TRT runs as high as 40 to 67% in some cohorts, and the risk correlates with peak testosterone exposure, not just average levels (Ohlander et al., 2018). Understanding your peak versus your trough helps you and your doctor assess cardiovascular risk more accurately (see our haemoglobin and haematocrit guide for action thresholds).

Trough vs peak: which one and why

"Trough" is the lowest point in your testosterone curve, immediately before your next injection. "Peak" is the highest point, typically one to five days after injection depending on the ester.

The Endocrine Society Clinical Practice Guideline recommends measuring testosterone at the midpoint between injections for intramuscular enanthate and cypionate, targeting a mid-normal range of 400 to 700 ng/dL (Bhasin et al., 2018). In practice, most TRT practitioners default to trough testing (drawing blood immediately before the next injection) because it is the most reproducible and conservative measurement point.

Why trough? Three reasons, and they compound on each other.

First, reproducibility. Trough occurs at a well-defined moment: the morning of your injection day, before you inject. There is no ambiguity about "how many hours post-injection" you tested. This makes comparison between blood tests over months and years meaningful. Peak testing, by contrast, requires hitting a narrow window that shifts depending on the ester, injection volume, injection site, and whether you injected IM or SubQ.

Second, clinical decision-making. Your trough represents the minimum guaranteed testosterone exposure your body receives between doses. If your trough is within range, your dose and frequency are adequate. If your trough is below range, you either need more testosterone or more frequent injections. Peak testing does not provide this information cleanly because there is no established "too high" testosterone threshold for an acute peak.

Third, consistency for trend tracking. If you are using VitalMetrics or any tracking tool to compare results over time, every draw needs to come from the same point in your injection cycle. Mixing a trough draw from January with a peak draw from April creates a phantom 300 to 500 ng/dL swing in your trend data that has nothing to do with your protocol.

When peak testing is useful

Peak testing has a narrower but real use case. It is worth checking your peak if:

• You experience side effects that seem tied to the first few days after injection (flushing, headache, high blood pressure, mood swings)
• You want to quantify your total exposure range to assess erythrocytosis or aromatisation risk
• Your doctor wants to confirm that a specific dose is not producing dangerously supraphysiological peaks

For most TRT patients, trough testing alone is sufficient. If you do test at peak, note the exact timing on your lab requisition so future comparisons are meaningful.

Blood draw timing by testosterone ester

Each ester has a different half-life, which determines how quickly testosterone is released and cleared. This directly affects when you should draw blood.

Testosterone enanthate

The most common TRT ester worldwide (standard in Australia, UK, and Europe). Half-life of approximately 4.5 days. Peaks at 24 to 48 hours post-injection, then tapers over the next five days.

On weekly injections, draw blood the morning of your injection day, before you inject. This captures the trough. On a Monday injection schedule, draw Monday morning fasted.

On twice-weekly injections (e.g., Monday/Thursday), the peak-to-trough swing is much smaller with split dosing. Draw before either injection. The difference between your Monday trough and Thursday trough will be minimal. A Phase II pharmacokinetic study found that subcutaneous enanthate at weekly dosing produces a peak-to-trough ratio of approximately 2.4, compared to 4.9 for less frequent IM dosing (Kaminetsky et al., 2015).

On daily or EOD SubQ, you are at near-steady state. Draw at any consistent time, but before that day's injection is simplest. The timing window matters least at this frequency because daily fluctuations are small.

Testosterone cypionate

Functionally interchangeable with enanthate. Slightly longer half-life (5 to 7 days). Peak occurs a bit later, at days four to five. The US TRT standard.

On weekly injections, same rule as enanthate: draw blood the morning of your injection day, before injecting.

On biweekly injections (200 mg every two weeks), this protocol still gets prescribed by some doctors despite producing the widest peak-to-trough swings. Peak at days four to five can hit 1,112 ng/dL while trough at day fourteen drops to approximately 400 ng/dL (Shoskes et al., 2016). If you are on this protocol, draw at trough (day thirteen or fourteen, morning of injection day). Consider discussing more frequent dosing with your doctor to reduce these swings.

Population pharmacokinetic modelling of depot testosterone cypionate estimates a median half-life of 4.05 days, with steady state reached after approximately three to five weeks of consistent dosing (Bi et al., 2018).

Testosterone propionate

Short ester with a half-life under two days. Peaks within hours of injection and is largely cleared by 48 hours (Fujioka et al., 1986). Requires every-other-day (EOD) or daily injections.

Draw blood before your next injection. Because propionate clears so fast, even a few hours of timing difference can shift your result significantly. Consistency is everything with this ester. Always draw at the same relative point.

Propionate is rarely used for TRT (the injection frequency is impractical for most), but it is common in pre-contest protocols and short cycles where rapid clearance is an advantage for PCT timing.

Testosterone undecanoate (Nebido/Aveed)

Ultra-long ester with a half-life of approximately 20 to 21 days. Administered as a 1000 mg injection every 10 to 14 weeks after a loading phase. Peaks at approximately seven days post-injection (Schubert et al., 2004).

Draw blood just before your next injection (at the end of the 10 to 14 week interval). This is your trough, and it is the most clinically relevant measurement. Trough values for undecanoate typically range from approximately 400 to 470 ng/dL (14 to 16 nmol/L) (Schubert et al., 2004). A mid-interval draw (around week five to six) will capture levels closer to the average, which can be useful for initial dose titration.

Note that steady state takes longer with undecanoate. Serum profiles do not stabilise until approximately the third or fourth injection (roughly 30 weeks from initiation). Blood tests during the first two injection cycles may not reflect your long-term levels.

Daily and subcutaneous injections: does timing still matter?

Daily or every-other-day injection protocols, whether IM or SubQ, produce near-steady-state testosterone levels. The peak-to-trough fluctuation shrinks to a fraction of what you see with weekly or biweekly dosing.

Subcutaneous injection adds another layer of stabilisation. SC testosterone enanthate produces a longer apparent half-life (approximately 10 days versus 7.2 days for IM) because subcutaneous tissue releases the depot more slowly through passive lymphatic drainage rather than muscle-contraction-driven absorption (Kaminetsky et al., 2015). The practical result: lower peaks, higher troughs, and a narrower fluctuation band.

A comparison study found that men on subcutaneous testosterone enanthate had significantly lower post-therapy estradiol and haematocrit compared to intramuscular testosterone cypionate, likely due to reduced supraphysiological peak exposure (Choi et al., 2022).

For daily or EOD protocols, blood draw timing becomes less critical. Draw before your injection at a consistent time, and your result will closely approximate your average daily level.

What time of day to get your blood drawn

Morning, fasted, before 10 AM. This rule exists for good reasons, though some of the reasoning changes once you are on exogenous testosterone.

For natural testosterone, diurnal variation is substantial. In men under 45, morning testosterone (7 to 9 AM) is 20 to 25% higher than afternoon levels, with absolute differences of 149 to 207 ng/dL (Brambilla et al., 2009). In men over 45, the amplitude shrinks to roughly 10% (Crawford et al., 2015). This is why pre-TRT diagnostic testing must be done in the early morning on two separate occasions.

On exogenous testosterone, diurnal variation is substantially reduced. Most injectable testosterone formulations produce a much flatter exposure profile compared to endogenous testosterone, though no single therapy completely replicates or eliminates the natural diurnal pattern (Pastuszak et al., 2022). So morning is less critical for testosterone itself once you are on a stable protocol.

But you still need morning fasted draws because of the other markers. A comprehensive TRT panel includes triglycerides, HDL, LDL, fasting glucose, and sometimes fasting insulin. Triglycerides can be overestimated by 20 to 30% in non-fasting samples. A mixed meal can suppress testosterone by an average of 123 ng/dL, with 56% of men transiently dropping below 300 ng/dL after eating (Gagliano-Juca et al., 2019). Even though this post-meal effect matters less on exogenous testosterone, keeping a fasted morning draw eliminates every possible confound.

How often should you get bloodwork on TRT

The testing cadence follows a predictable pattern: frequent early on, then less frequent once you are stable.

The schedule

The Endocrine Society recommends retesting at 3 to 12 months after initiation, then annually (Bhasin et al., 2018). The AUA recommends haematocrit monitoring at 3, 6, and 12 months in the first year (Mulhall et al., 2018).

Haematocrit action thresholds

Erythrocytosis is the most common adverse effect of injectable TRT, with incidence approaching 40% for intramuscular formulations (Ohlander et al., 2018). The 2024 British Journal of General Practice clinical guideline for AAS users sets clear thresholds: haematocrit above 0.52 requires dose reduction or cessation with repeat testing; haematocrit above 0.60 triggers urgent haematology referral (Gibbons et al., 2024). For more on managing this, see our haemoglobin and haematocrit guide and our article on the iron paradox on TRT.

Gels, creams, and pellets: timing differences

Not everyone uses injectable testosterone. Topical and pellet formulations have their own timing rules.

Testosterone gel

The gel timing controversy is real. Some guidelines say draw 2 to 4 hours after application (to capture the peak). Others say draw before application (to capture the trough). The evidence supports caution: a study by Swerdloff et al. (2015) found that ambulatory samples drawn 2 hours post-application did not correlate significantly with the 24-hour average testosterone concentration, with high within-subject variability dominating the measurement (Swerdloff et al., 2015). A single post-application draw is not a reliable indicator of your steady-state exposure.

Draw blood before applying your gel that morning. This gives you a consistent pre-application trough that is comparable across tests. If your doctor specifically wants a post-application level, apply the gel and draw blood exactly 2 hours later, but use the same timing for every subsequent test.

Scrotal testosterone cream

Scrotal skin has significantly higher 5-alpha-reductase activity, which means scrotal cream produces higher DHT conversion than standard topical testosterone. Testosterone peaks at 1.9 to 2.8 hours after application, but DHT peaks later at approximately 4.9 hours (Iyer et al., 2017).

If you are monitoring DHT (for hair loss or prostate concerns), draw blood at 5 hours post-application. If you are monitoring testosterone alone, draw before application or at 2 hours post-application.

Testosterone pellets

Pellets provide the most stable release profile. Levels peak at approximately 4 weeks post-implantation and maintain therapeutic levels for 4 to 6 months before gradually declining (Kelleher et al., 2004).

Draw blood at 4 weeks (peak check), 3 months (stability confirmation), and 5 to 6 months (pre-reinsertion trough). If you suspect the pellets have extruded or are not releasing properly, check LH and FSH; gonadotropin levels are more sensitive than serum testosterone for detecting suboptimal pellet function.

Blast and cycle bloodwork: different rules

Everything above applies to stable, therapeutic-dose TRT. If you are using supraphysiological doses (a blast), the timing rules change because the clinical goals change.

Mid-cycle testing (weeks 4 to 6)

For long-ester compounds like testosterone enanthate or cypionate, steady state is reached at approximately 3 to 4 weeks. The optimal window for mid-cycle bloodwork is weeks 4 to 6: levels are stable enough to be representative but early enough to catch problems before they compound.

What to test mid-cycle:

• Haematocrit and haemoglobin (erythrocytosis risk is highest with injectables)
• ALT and AST (especially if running oral compounds)
• HDL and LDL (HDL crashes rapidly on most anabolics)
• Estradiol (if running aromatisable compounds)
• Prolactin (only if running 19-nors like nandrolone or trenbolone)

Blast-to-cruise transition

When dropping from blast doses to a TRT cruise, your bloodwork will not reflect the cruise dose for several weeks. Residual ester from the blast continues releasing from the depot. For testosterone enanthate (half-life 4.5 days), five half-lives equals approximately 22 days. For longer compounds like nandrolone decanoate (depot half-life of 6 days), clearance takes 4 to 5 weeks (Wijnand et al., 1985).

Wait at least 5 to 6 weeks after your last blast injection before drawing blood to assess your cruise. Testing earlier will show falsely elevated levels that do not represent your new steady state.

Post-cycle HPTA recovery testing

After stopping exogenous testosterone entirely (with or without PCT), LH and FSH recovery takes weeks to months. Testing too early is one of the most common mistakes.

A scoping review of HPTA recovery found that testosterone recovery ranged from 10 days to over 12 months after cessation, with longer durations observed in long-term, heavy users (Solanki et al., 2023). Another study found that 26% of former AAS users still had testosterone below 200 ng/dL despite months of abstinence (Kanayama et al., 2015).

The 2024 BJGP clinical guideline recommends checking testosterone at 12 weeks after cessation, with a repeat at 8 to 12 weeks later if still suppressed, before considering secondary care referral (Gibbons et al., 2024).

Do not test LH, FSH, or "natural" testosterone while you are still on exogenous testosterone. They will be fully suppressed (LH typically below 1.0 IU/L) and the result tells you nothing (Miranda et al., 2022).

Common timing mistakes that skew your results

Testing too soon after a dose change

Steady state for injectable enanthate and cypionate takes approximately 3 to 5 weeks (3 to 5 half-lives). Drawing blood at week one or two after a dose adjustment does not reflect your new protocol. The Endocrine Society recommends waiting at least 4 to 6 weeks before retesting after any dose or frequency change (Bhasin et al., 2018).

Testing at peak and panicking about estradiol

Because estradiol aromatises in proportion to free testosterone, the peak testosterone window (days 1 to 5 for enanthate/cypionate) is also peak estradiol. Testing at this point will show E2 levels 2 to 3 times higher than at trough. This is the single most common trigger for unnecessary anastrozole use. Always compare estradiol results that were drawn at the same point in your injection cycle.

Inconsistent timing between tests

Comparing a trough draw from three months ago with a mid-cycle draw today creates a phantom swing that has nothing to do with your health. If your January result was 550 ng/dL at trough and your April result is 900 ng/dL at peak, you have not "gotten worse." You measured at two different points on the same wave.

Not fasting

A glucose load can suppress testosterone by 25%, with the effect detectable at the 30-minute mark and lasting at least 2 hours (Caronia et al., 2013). Even on exogenous testosterone where this matters less for the testosterone number itself, your triglycerides and glucose will be unreliable non-fasting. Just fast. It removes every confound.

The "2 PM appointment" problem

If your GP schedules an afternoon slot, your pre-TRT diagnostic test will be systematically biased downward. In men under 45, an afternoon draw can read 150 to 207 ng/dL lower than a morning draw (Brambilla et al., 2009). This is large enough to shift a borderline result across the diagnostic threshold in either direction. For monitoring on TRT, the diurnal effect is smaller, but morning draws remain the standard for consistency and because the rest of your panel (lipids, glucose) benefits from a fasted morning draw.

Testing too soon after PCT

Drawing blood at 2 to 4 weeks into PCT and seeing suppressed testosterone, low LH, and low FSH is not PCT failure. That is the expected result at that stage. Recovery probabilities for spermatogenesis are 67% at 6 months, 90% at 12 months, and 96% at 16 months (McBride & Coward, 2016). The meaningful checkpoints are 12 weeks and 24 weeks post-cessation, not 2 to 4 weeks.

Key takeaways

• Always test at the same point in your injection cycle. Trough (morning of injection day, before injecting) is the simplest and most reproducible option.
• The peak-to-trough swing on weekly injectable TRT can exceed 700 ng/dL. This is a timing artifact, not a health change.
• Splitting your dose (twice weekly or daily) reduces the swing and makes draw timing less critical.
• Morning fasted draws (7 to 10 AM) remain the standard because your panel includes lipids and glucose, even though exogenous testosterone itself shows minimal diurnal variation.
• Wait 6 to 8 weeks after any protocol change before retesting. Steady state takes time.
• For blasts, draw mid-cycle at weeks 4 to 6. For blast-to-cruise transitions, wait 5 to 6 weeks before drawing.
• For post-cycle recovery, test at 12 weeks and again at 24 weeks. Do not test LH/FSH while still on exogenous testosterone.
• Consistency beats perfection. The most useful blood test is one drawn at the exact same conditions as the last one.

---

References

1. Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 103(5), 1715-1744. PubMed

2. Shoskes, J. J., Wilson, M. K., & Spinner, M. L. (2016). Pharmacology of testosterone replacement therapy preparations. Translational Andrology and Urology, 5(6), 834-843. PubMed

3. Ohlander, S. J., Varghese, B., & Pastuszak, A. W. (2018). Erythrocytosis following testosterone therapy. Sexual Medicine Reviews, 6(1), 77-85. PubMed

4. Al-Sharefi, A., & Quinton, R. (2020). Current national and international guidelines for the management of male hypogonadism. Endocrinology and Metabolism, 35(3), 526-540. PubMed

5. Nankin, H. R. (1987). Hormone kinetics after intramuscular testosterone cypionate. Fertility and Sterility, 47(6), 1004-1009. PubMed

6. Kaminetsky, J., Jaffe, J. S., & Swerdloff, R. S. (2015). Pharmacokinetic profile of subcutaneous testosterone enanthate delivered via a novel, prefilled single-use autoinjector. Sexual Medicine, 3(4), 269-279. PubMed

7. Bi, Y., Perry, P. J., Ellerby, M., & Murry, D. J. (2018). Population pharmacokinetic/pharmacodynamic modeling of depot testosterone cypionate. CPT: Pharmacometrics & Systems Pharmacology, 7(4), 259-268. PubMed

8. Fujioka, M., Shinohara, Y., Baba, S., Irie, M., & Inoue, K. (1986). Pharmacokinetic properties of testosterone propionate in normal men. Journal of Clinical Endocrinology & Metabolism, 63(6), 1361-1364. PubMed

9. Schubert, M., Minnemann, T., Hubler, D., Rouskova, D., Christoph, A., Oettel, M., Ernst, M., Mellinger, U., Krone, W., & Jockenhovel, F. (2004). Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation. Journal of Clinical Endocrinology & Metabolism, 89(11), 5429-5434. PubMed

10. Brambilla, D. J., Matsumoto, A. M., Araujo, A. B., & McKinlay, J. B. (2009). The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. Journal of Clinical Endocrinology & Metabolism, 94(3), 907-913. PubMed

11. Crawford, E. D., Poage, W., Nyhuis, A., Price, D. A., Dowsett, S. A., Gelwicks, S., & Muram, D. (2015). Measurement of testosterone: how important is a morning blood draw? Current Medical Research and Opinion, 31(10), 1911-1917. PubMed

12. Pastuszak, A. W., Gittelman, M., Tursi, J. P., Jaffe, J. S., Schofield, D., & Miner, M. M. (2022). Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age. Andrology, 10(2), 209-222. PubMed

13. Gagliano-Juca, T., Li, Z., Pencina, K. M., et al. (2019). Oral glucose load and mixed meal feeding lowers testosterone levels in healthy eugonadal men. Endocrine, 63(1), 149-156. PubMed

14. Livingston, M., Hackett, G., Ramachandran, S., & Heald, A. (2021). Is a fasting testosterone level really necessary for the determination of androgen status in men? Clinica Chimica Acta, 521, 64-69. PubMed

15. Mulhall, J. P., Trost, L. W., Brannigan, R. E., et al. (2018). Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology, 200(2), 423-432. PubMed

16. Gibbons, S. M., Moulding, M., Bailey, K., et al. (2024). Essential blood testing in the patient using androgenic anabolic steroids: a clinical practice guideline for primary care. British Journal of General Practice, 74(741), 187-190. PubMed

17. Choi, E. J., Xu, P., Barham, D., El-Khatib, F. M., Yafi, F. A., & Kavoussi, P. K. (2022). Comparison of outcomes for hypogonadal men treated with intramuscular testosterone cypionate versus subcutaneous testosterone enanthate. Journal of Urology, 207(3), 677-683. PubMed

18. Swerdloff, R. S., Pak, Y., Wang, C., et al. (2015). Serum testosterone level variability in T gel-treated older hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 100(9), 3280-3287. PubMed

19. Iyer, R., Mok, S. F., Savkovic, S., et al. (2017). Pharmacokinetics of testosterone cream applied to scrotal skin. Andrology, 5(4), 725-731. PubMed

20. Kelleher, S., Howe, C., Conway, A. J., & Handelsman, D. J. (2004). Testosterone release rate and duration of action of testosterone pellet implants. Clinical Endocrinology, 60(4), 420-428. PubMed

21. Caronia, L. M., Dwyer, A. A., Hayden, D., Amati, F., Pitteloud, N., & Hayes, F. J. (2013). Abrupt decrease in serum testosterone levels after an oral glucose load in men. Clinical Endocrinology, 78(2), 291-296. PubMed

22. Solanki, P., Eu, B., Smith, J., Allan, C., & Lee, K. (2023). Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review. Endocrine Connections, 12(12), e230358. PubMed

23. Kanayama, G., Hudson, J. I., & Pope, H. G., Jr. (2015). Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids. Addiction, 110(5), 823-831. PubMed

24. McBride, J. A., & Coward, R. M. (2016). Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian Journal of Andrology, 18(3), 373-380. PubMed

25. Miranda, E. P., Schofield, E., Matsushita, K., et al. (2022). Luteinizing hormone suppression profiles in men treated with exogenous testosterone. Journal of Sexual Medicine, 19(9), 1359-1365. PubMed

26. Wijnand, H. P., Bosch, A. M., & Donker, C. W. (1985). Pharmacokinetics of nandrolone after intramuscular administration of nandrolone decanoate. Acta Endocrinologica Supplementum, 271, 19-30. PubMed